Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Mucous membrane pemphigoid following reduced intensity conditioning allogeneic haematopoietic SCT for biphenotypic leukaemia

Bone Marrow Transplantation volume 45, pages 195–196 (2010)Cite this article

Mucous membrane pemphigoid (MMP) encompasses a group of autoimmune, chronic inflammatory, subepithelial blistering disorders affecting the mucous membranes characterized by deposition of IgG, IgA or C3 on the basement membrane zone (BMZ). There is predilection for involvement of the oropharynx, nasopharynx, larynx, conjunctiva, anogenital and oesophagus with or without skin involvement.1, 2 We report an unusual case of MMP that developed in a gentleman following a reduced intensity conditioning haematopoietic SCT.

A 51-year-old gentleman with acute biphenotypic leukaemia, underwent a reduced intensity conditioning haematopoietic SCT. He received a cell dose of CD34 8.49 × 106/kg (PBPCs) from an unrelated male HLA-C mismatched donor. The conditioning protocol comprised fludarabine (30 mg/m2 daily × 5days), i.v. BU (3.2 mg/kg daily × 2 days) and alemtuzumab (20 mg daily × 5 days) with ciclosporin post transplant for GVHD prophylaxis. He had no significant bacterial viral infections in the immediate peri or post transplant period. His days 28, 56 and 100 BM assessment confirmed that he was in morphological remission with full donor chimerism, and he had no evidence of GVHD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Chan LS, Ahmed AR, Anhalt GJ, Bernauer W, Cooper KD, Elder MJ et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment and prognostic indicators. Arch Dermatol 2002; 138: 370–379.

    PubMed  Google Scholar 

  2. Seth RK, Su GW, Pflugfelder SC . Mucous membrane pemphigoid in a patient with chronic lymphocytic leukaemia. Cornea 2004; 23: 740–743.

    Article  PubMed  Google Scholar 

  3. Aisa Y, Mori T, Nakazato T, Yamazaki R, Yamagami J, Amagai M et al. Cicatricial pemphigoid of the oropharynx after allogeneic stem cell transplantation for relapsed follicular lymphoma. Int J Hematol 2005; 82: 266–269.

    Article  PubMed  Google Scholar 

  4. Saravanan K, Baer ST, Meredith A, Dyson A, von der Werth J . Benign mucous membrane pemphigoid of the upper aero-digestive tract: rare paraneoplastic syndrome presentation in renal cell carcinoma. J Laryngol Otol 2006; 120: 237–239.

    Article  CAS  PubMed  Google Scholar 

  5. Rutar T, Chan MF, Acharya NR, Naseri A . Cicatrising conjunctivitis due to paraneoplastic pemphigoid. Br J Opthalmol 2007; 91: 1562–1563.

    Article  Google Scholar 

  6. Setterfield J, Shirlaw PJ, Lazarova Z, Bryant BM, Bhogal BS, Harman K et al. Paraneoplastic cicatricial pemphigoid. Br J Dermato 1999; 141: 127–131.

    Article  CAS  Google Scholar 

  7. Egan CA, Lazarova Z, Darling TN, Yee C, Yancey KB . Anti-epiligrin cicatricial pemphigoid and relative risk of cancer. Lancet 2001; 357: 1850–1851.

    Article  CAS  PubMed  Google Scholar 

  8. Setterfield J, Theron J, Vaughn RW, Welsh KI, Mallon E, Wojnarowska F et al. Mucous membrane pemphigoid: HLA-DQB1*0301 is associated with all clinical sites of involvement and may be linked to antibasement membrane IgG production. Br J Dermatol 2001; 145: 406–414.

    Article  CAS  PubMed  Google Scholar 

  9. Izumi R, Fujimoto M, Yazawa N, Nakashima H, Asashima N, Watanabe R et al. Bullous pemphigoid positive for anti-BP180 and anti-laminin 5 antibodies in a patient with graft-vs-host-disease. J Am Acad Dermatol 2007; 56: s94–s97.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematological Medicine, Kings College Hospital NHS Foundation Trust, London, UK

    S Mahmood, Z Y Lim, G J Mufti & A Pagliuca

  2. Department of Dermatology, Kings College Hospital NHS Foundation Trust, London, UK

    E Benton & A du Vivier

  3. St John's Institute of Dermatology, St Thomas Hospital, London, UK. E-mail: tony.pagliuca@kch.nhs.uk,

    B Bhogal

Authors
  1. S Mahmood
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Z Y Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E Benton
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A du Vivier
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B Bhogal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G J Mufti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Pagliuca
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mahmood, S., Lim, Z., Benton, E. et al. Mucous membrane pemphigoid following reduced intensity conditioning allogeneic haematopoietic SCT for biphenotypic leukaemia. Bone Marrow Transplant 45, 195–196 (2010). https://doi.org/10.1038/bmt.2009.98

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.98

Search

Advanced search

Quick links